Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Mitchell S von Itzstein"'
Autor:
Hong Mu-Mosley, Mitchell S. von Itzstein, Farjana Fattah, Jialiang Liu, Chengsong Zhu, Yang Xie, Edward K. Wakeland, Jason Y. Park, Brad S. Kahl, Catherine S. Diefenbach, David E. Gerber
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
ABSTRACTImmune checkpoint inhibitors (ICI) are increasingly used in combination. To understand the effects of different ICI categories, we characterized changes in circulating autoantibodies in patients enrolled in the E4412 trial (NCT01896999) of br
Externí odkaz:
https://doaj.org/article/51d24a432465425b8ddda0a091d602da
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Immune checkpoint inhibitors (ICIs) have revolutionized oncology treatment. However, their success is mitigated by the recognition that ICI-induced immune-related adverse events (irAEs) pose considerable challenges to patients and clinicians. These a
Externí odkaz:
https://doaj.org/article/b6e8f51070cd4f08b48ec890699dc7aa
Autor:
Jarushka Naidoo, Igor Puzanov, Paolo A Ascierto, Marc S Ernstoff, Douglas B Johnson, Fei Ye, Mitchell S von Itzstein, David E Gerber, Benjamin Switzer, Aliyah Pabani, Hannah Burnette, Run Fan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024)
Background Artificial intelligence (AI) chatbots have become a major source of general and medical information, though their accuracy and completeness are still being assessed. Their utility to answer questions surrounding immune-related adverse even
Externí odkaz:
https://doaj.org/article/10149fdee8db4c7899ea1632bcd5d0b9
Autor:
Mitchell S. von Itzstein, Yuqiu Yang, Yiqing Wang, David Hsiehchen, Thomas Y. Sheffield, Farjana Fattah, Vinita Popat, Murtaza Ahmed, Jade Homsi, Jonathan E. Dowell, Sawsan Rashdan, Jay Lohrey, Hans J. Hammers, Randall S. Hughes, Tao Wang, Yang Xie, David E. Gerber
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundA useful clinical biomarker requires not only association but also a consistent temporal relationship. For instance, chemotherapy-induced neutropenia and epidermal growth-factor inhibitor-related acneiform rash both occur within weeks of tr
Externí odkaz:
https://doaj.org/article/e1b2ad32701a42d2b479f1f97e15f912
Autor:
Yang Xie, Shaheen Khan, Prithvi Raj, Edward K Wakeland, Mitchell S von Itzstein, Farjana Fattah, Jason Y Park, David Hsiehchen, Jared Ostmeyer, David E Gerber, Mary Gwin, Rodrigo Catalan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 8 (2023)
Background Immune checkpoint inhibitor (ICI) therapies may cause unpredictable and potentially severe autoimmune toxicities termed immune-related adverse events (irAEs). Because T cells mediate ICI effects, T cell profiling may provide insight into t
Externí odkaz:
https://doaj.org/article/3479b528102c43d8a55d222dbb9e00ea
Autor:
Vatsala Mundra, Yuqiu Yang, Mitchell S. von Itzstein, Farjana Fattah, Amrit S. Gonugunta, Raquibul Hannan, Laurentiu M. Pop, Yuanyuan Zhang, Yiqing Wang, Thomas Sheffield, Yang Xie, Jonathan E. Dowell, Jade Homsi, Sawsan Rashdan, Jason Park, Quan-Zhen Li, Edward K. Wakeland, David E. Gerber
Publikováno v:
Translational Oncology, Vol 34, Iss , Pp 101689- (2023)
Introduction: Preclinical studies have demonstrated the ability of radiation therapy (RT) to augment immune response and tumor control by immune checkpoint inhibitors (ICI). However, numerous clinical trials combining RT and ICI have yielded relative
Externí odkaz:
https://doaj.org/article/18122791074543dcbbb6c31a1100dec6
Publikováno v:
Journal of Medical Case Reports, Vol 16, Iss 1, Pp 1-5 (2022)
Abstract Background Pseudoprogression, the initial apparent worsening of cancer prior to eventual improvement, is a documented feature of immune checkpoint inhibitor administration and presents a challenge to clinicians distinguishing true progressio
Externí odkaz:
https://doaj.org/article/a0996b4c5acb4a62b9b658e6790a6621
Autor:
David Hsiehchen, Abdul Rafeh Naqash, Magdalena Espinoza, Mitchell S. Von Itzstein, Alessio Cortellini, Biagio Ricciuti, Dwight H. Owen, Mehak Laharwal, Yukihiro Toi, Michael Burke, Yang Xie, David E. Gerber
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The timing of immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI) is highly variable. Although the development of irAE has been associated with ICI clinical benefit, how irAE timing influences this association is u
Externí odkaz:
https://doaj.org/article/314b3c66dd194bac9be88d3b95ef3bff
Autor:
Shelby Edmondson, BA, Mitchell S. von Itzstein, MD, Brian Reys, MS, Melissa Mayer, BA, Jeffrey Gagan, MD, David E. Gerber, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 8, Pp 100368- (2022)
Introduction: Heritable lung cancer may occur in the context of germline TP53 mutations (Li-Fraumeni syndrome). Limited cases of intrafamily tumor genomic characteristics have been reported. Main concerns, Important Clinical Findings, Primary Diagnos
Externí odkaz:
https://doaj.org/article/5a5e58e40af34b6182b5ff3a6781e1b3
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 3, Pp 100291- (2022)
Introduction: EGFR L747P mutations occur rarely, with limited preclinical research and case reports suggesting resistance to osimertinib. Main Concerns, Important Clinical Findings, Primary Diagnoses, Interventions, Outcomes: An 84-year-old white mal
Externí odkaz:
https://doaj.org/article/d7ee8e1020fb49318409abceb0196f76